ATE430572T1 - Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie - Google Patents
Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesieInfo
- Publication number
- ATE430572T1 ATE430572T1 AT03780370T AT03780370T ATE430572T1 AT E430572 T1 ATE430572 T1 AT E430572T1 AT 03780370 T AT03780370 T AT 03780370T AT 03780370 T AT03780370 T AT 03780370T AT E430572 T1 ATE430572 T1 AT E430572T1
- Authority
- AT
- Austria
- Prior art keywords
- methoxyadenosine
- treatment
- pain
- spongosin
- hyperalgesia
- Prior art date
Links
- AJACDNCVEGIBNA-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-amino-2-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(OC)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O AJACDNCVEGIBNA-KQYNXXCUSA-N 0.000 title abstract 5
- AJACDNCVEGIBNA-UHFFFAOYSA-N 2-Methoxyadenosine Natural products C12=NC(OC)=NC(N)=C2N=CN1C1OC(CO)C(O)C1O AJACDNCVEGIBNA-UHFFFAOYSA-N 0.000 title abstract 5
- 208000004454 Hyperalgesia Diseases 0.000 title 1
- 208000035154 Hyperesthesia Diseases 0.000 title 1
- 150000003838 adenosines Chemical class 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0228723.3A GB0228723D0 (en) | 2002-12-09 | 2002-12-09 | Treatment of pain |
| PCT/GB2003/005379 WO2004052377A1 (en) | 2002-12-09 | 2003-12-09 | Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE430572T1 true ATE430572T1 (de) | 2009-05-15 |
Family
ID=9949371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03780370T ATE430572T1 (de) | 2002-12-09 | 2003-12-09 | Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8252766B2 (https=) |
| EP (1) | EP1581235B1 (https=) |
| JP (2) | JP4836454B2 (https=) |
| KR (1) | KR101122495B1 (https=) |
| CN (2) | CN101264097B (https=) |
| AT (1) | ATE430572T1 (https=) |
| AU (1) | AU2003288451B2 (https=) |
| CA (1) | CA2507918A1 (https=) |
| CY (1) | CY1109229T1 (https=) |
| DE (1) | DE60327557D1 (https=) |
| DK (1) | DK1581235T3 (https=) |
| ES (1) | ES2326532T3 (https=) |
| GB (2) | GB0228723D0 (https=) |
| NO (1) | NO20053042L (https=) |
| NZ (1) | NZ540353A (https=) |
| PT (1) | PT1581235E (https=) |
| SI (1) | SI1581235T1 (https=) |
| WO (1) | WO2004052377A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
| GB0305149D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
| CA2557285A1 (en) * | 2004-03-05 | 2005-09-15 | Cambridge Biotechnology Limited | Adenosine receptor agonists |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| US8399400B2 (en) * | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
| GB0426394D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| GB0610867D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| WO2008000743A2 (en) | 2006-06-27 | 2008-01-03 | Biovitrum Ab (Publ) | Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists |
| BRPI0713902A2 (pt) | 2006-06-27 | 2012-11-27 | Biovitrum Ab | compostos terapêuticos |
| AU2007263728A1 (en) | 2006-06-27 | 2008-01-03 | Biovitrum Ab (Publ) | Adenosine derivatives for the treatment of pain |
| JP2011509305A (ja) * | 2008-01-09 | 2011-03-24 | ピージーエックスヘルス、リミテッド、ライアビリティー、カンパニー | Ａ２ａｒアゴニストによる神経障害性疼痛の髄腔内治療 |
| US8221791B1 (en) | 2008-12-10 | 2012-07-17 | University Of Central Florida Research Foundation, Inc. | Silica-based antibacterial and antifungal nanoformulation |
| US20120165285A1 (en) * | 2009-07-09 | 2012-06-28 | Peter Richardson | Combined preparation for use as a medicament |
| US20130123208A1 (en) * | 2010-05-12 | 2013-05-16 | The Regents of the University of Colorado, a body corporation | Method of treating multiple sclerosis with adenosine receptor agonists |
| EP2631345B1 (en) * | 2012-02-27 | 2019-09-04 | Electrolux Home Products Corporation N.V. | Washing tub unit and washing machine |
| US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| US10774110B2 (en) * | 2016-02-04 | 2020-09-15 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE792155A (fr) | 1971-12-01 | 1973-05-30 | Takeda Chemical Industries Ltd | Nouveaux derives de l'adenosine et leur procede de production |
| JPS4861498A (https=) | 1971-12-01 | 1973-08-28 | ||
| DE2359536C2 (de) * | 1972-12-08 | 1984-08-02 | Takeda Chemical Industries, Ltd., Osaka | 2,6-Diaminonebularinderivate |
| JPS5549594B2 (https=) | 1972-12-08 | 1980-12-12 | ||
| JPS5461194A (en) * | 1977-10-21 | 1979-05-17 | Takeda Chem Ind Ltd | Preparation of n22substituted 2*66diaminonebularin |
| JPS5461195A (en) | 1977-10-21 | 1979-05-17 | Takeda Chem Ind Ltd | N2-substituted phenyl-2,6-diaminonebularin |
| US4705758A (en) * | 1984-06-19 | 1987-11-10 | Warner-Lambert Company | Adenosine receptor assay and kit |
| US5231086A (en) * | 1985-09-24 | 1993-07-27 | Item Development Aktiebolag | Continuous administration adenosine to increase myocardial blood flow |
| US5104859A (en) * | 1985-09-24 | 1992-04-14 | Solimedco Aktiebolag | Continuous administration of adenosine to reduce pulmonary vascular resistance |
| US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US5140015A (en) | 1990-02-20 | 1992-08-18 | Whitby Research, Inc. | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents |
| US6004945A (en) * | 1990-05-10 | 1999-12-21 | Fukunaga; Atsuo F. | Use of adenosine compounds to relieve pain |
| US5677290A (en) * | 1990-05-10 | 1997-10-14 | Fukunaga; Atsuo F. | Therapeutic use of adenosine compounds as surgical anesthetics |
| US5679650A (en) * | 1993-11-24 | 1997-10-21 | Fukunaga; Atsuo F. | Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine |
| US6180616B1 (en) * | 1990-05-10 | 2001-01-30 | Atsuo F. Fukunaga | Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function |
| WO1994023723A1 (en) | 1993-04-15 | 1994-10-27 | New York University | Adenosine receptor agonists for the promotion of wound healing |
| US5683989A (en) * | 1993-12-17 | 1997-11-04 | Novo Nordisk A/S | Treatment of ischemias by administration of 2,N6 -substituted adenosines |
| SE9401499D0 (sv) | 1994-05-02 | 1994-05-02 | Item Dev Ab | New method of treatment |
| AU2546195A (en) | 1994-05-10 | 1995-11-29 | Novartis Ag | Adenosine derivatives |
| US5596094A (en) * | 1994-05-26 | 1997-01-21 | Sandoz Ltd. | Process for preparing 2' -0- alkyl adenosine derivatives |
| US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
| IT1275420B (it) | 1995-06-02 | 1997-08-05 | Schering Plough S P A | Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261 |
| AU7449598A (en) | 1997-05-23 | 1998-12-11 | Nippon Shinyaku Co. Ltd. | Medicinal composition for prevention or treatment of hepatopathy |
| US6110902A (en) * | 1997-06-23 | 2000-08-29 | Moehler; Hanns | Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine |
| AU8764398A (en) | 1997-07-29 | 1999-02-22 | Medco Research, Inc. | N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators |
| US6440455B1 (en) | 1997-09-02 | 2002-08-27 | Children's Medical Center Corporation | Methods for modulating the axonal outgrowth of central nervous system neurons |
| GB9723590D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| JP2002500188A (ja) | 1998-01-08 | 2002-01-08 | ザ・ユニバーシティ・オブ・バージニア・パテント・ファウンデーション | Ａ２ａアデノシンレセプター作動因子 |
| GB9913932D0 (en) | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
| US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
| CA2551169A1 (en) | 2002-12-23 | 2004-07-08 | Global Cardiac Solutions Pty Ltd | Organ preconditioning, arrest, protection, preservation and recovery |
| GB0305150D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Use of therapeutic compounds |
| GB0305153D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Identification of therapeutic compounds |
| GB0305149D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
| CA2557285A1 (en) | 2004-03-05 | 2005-09-15 | Cambridge Biotechnology Limited | Adenosine receptor agonists |
| US8407664B2 (en) | 2005-12-30 | 2013-03-26 | Sap Ag | Software model business objects |
-
2002
- 2002-12-09 GB GBGB0228723.3A patent/GB0228723D0/en not_active Ceased
-
2003
- 2003-12-09 AU AU2003288451A patent/AU2003288451B2/en not_active Ceased
- 2003-12-09 KR KR1020057010441A patent/KR101122495B1/ko not_active Expired - Fee Related
- 2003-12-09 ES ES03780370T patent/ES2326532T3/es not_active Expired - Lifetime
- 2003-12-09 DE DE60327557T patent/DE60327557D1/de not_active Expired - Lifetime
- 2003-12-09 CN CN2008100922507A patent/CN101264097B/zh not_active Expired - Fee Related
- 2003-12-09 EP EP03780370A patent/EP1581235B1/en not_active Expired - Lifetime
- 2003-12-09 DK DK03780370T patent/DK1581235T3/da active
- 2003-12-09 AT AT03780370T patent/ATE430572T1/de active
- 2003-12-09 CA CA002507918A patent/CA2507918A1/en not_active Abandoned
- 2003-12-09 JP JP2004558826A patent/JP4836454B2/ja not_active Expired - Fee Related
- 2003-12-09 SI SI200331633T patent/SI1581235T1/sl unknown
- 2003-12-09 US US10/537,564 patent/US8252766B2/en not_active Expired - Fee Related
- 2003-12-09 WO PCT/GB2003/005379 patent/WO2004052377A1/en not_active Ceased
- 2003-12-09 GB GB0328548A patent/GB2396108B/en not_active Expired - Fee Related
- 2003-12-09 PT PT03780370T patent/PT1581235E/pt unknown
- 2003-12-09 NZ NZ540353A patent/NZ540353A/en not_active IP Right Cessation
- 2003-12-09 CN CNB2003801055073A patent/CN100471503C/zh not_active Expired - Fee Related
-
2005
- 2005-06-21 NO NO20053042A patent/NO20053042L/no not_active Application Discontinuation
-
2009
- 2009-07-14 CY CY20091100733T patent/CY1109229T1/el unknown
-
2010
- 2010-08-20 US US12/859,932 patent/US20110184065A1/en not_active Abandoned
- 2010-12-03 JP JP2010270287A patent/JP2011132229A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP4836454B2 (ja) | 2011-12-14 |
| EP1581235B1 (en) | 2009-05-06 |
| CN101264097B (zh) | 2011-10-05 |
| GB0328548D0 (en) | 2004-01-14 |
| GB0228723D0 (en) | 2003-01-15 |
| WO2004052377A1 (en) | 2004-06-24 |
| NZ540353A (en) | 2006-11-30 |
| US20110184065A1 (en) | 2011-07-28 |
| CN100471503C (zh) | 2009-03-25 |
| EP1581235A1 (en) | 2005-10-05 |
| KR101122495B1 (ko) | 2012-03-15 |
| US8252766B2 (en) | 2012-08-28 |
| CY1109229T1 (el) | 2013-09-04 |
| GB2396108A (en) | 2004-06-16 |
| JP2006514638A (ja) | 2006-05-11 |
| AU2003288451A1 (en) | 2004-06-30 |
| DK1581235T3 (da) | 2009-08-31 |
| CN101264097A (zh) | 2008-09-17 |
| SI1581235T1 (sl) | 2009-10-31 |
| DE60327557D1 (de) | 2009-06-18 |
| HK1086186A1 (zh) | 2006-09-15 |
| GB2396108B (en) | 2005-08-03 |
| PT1581235E (pt) | 2009-07-07 |
| AU2003288451B2 (en) | 2009-06-04 |
| KR20050089815A (ko) | 2005-09-08 |
| ES2326532T3 (es) | 2009-10-14 |
| JP2011132229A (ja) | 2011-07-07 |
| US20070010475A1 (en) | 2007-01-11 |
| CN1723026A (zh) | 2006-01-18 |
| CA2507918A1 (en) | 2004-06-24 |
| NO20053042L (no) | 2005-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE430572T1 (de) | Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie | |
| NZ515567A (en) | Method for treating chronic pain using MEK inhibitors | |
| MY151032A (en) | Treatment of tnf? related disorders | |
| ATE250932T1 (de) | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer | |
| EP1670450B8 (en) | Pharmaceutical compositions and method of using levodopa and carbidopa | |
| ATE524125T1 (de) | Platte und schrauben zur behandlung von knochenfrakturen | |
| MXPA05005107A (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores. | |
| WO2006052718A3 (en) | Farnesyltransferase inhibitors for treating sepsis | |
| EA200401365A1 (ru) | Способы лечения илеуса | |
| MXPA05006359A (es) | Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos. | |
| TW200510397A (en) | Conjugated complement cascade inhibitors | |
| ATE401087T1 (de) | Verbindungen zur schmerzbehandlung | |
| DK1648484T3 (da) | Fremgangsmåde til behandling af arthritis-tilstande | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| SI1546182T1 (sl) | Sestavki in postopki za diagnozo in zdravljenje tumorja | |
| ATE516027T1 (de) | Orazamid orotat zur vorbeugung von leberschäden | |
| ATE443044T1 (de) | Tace inhibitoren | |
| BR0312470A (pt) | Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto | |
| DE60334094D1 (de) | Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden | |
| ATE453386T1 (de) | Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten | |
| ATE392212T1 (de) | Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen | |
| TW200508196A (en) | Hydroxamic acids useful in the treatment of hyper-proliferative disorders | |
| ATE412411T1 (de) | Pmcol zur behandlung von prostatakrebs | |
| TW200642688A (en) | New use of PDE7 inhibitors | |
| DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1581235 Country of ref document: EP |